David W Kimberlin, Penelope M Jester, Pablo J Sánchez, Amina Ahmed, Ravit Arav-Boger, Marian G Michaels, Negar Ashouri, Janet A Englund, Benjamin Estrada, Richard F Jacobs, José R Romero, Sunil K Sood, M Suzanne Whitworth, Mark J Abzug, Mary T Caserta, Sandra Fowler, Jorge Lujan-Zilbermann, Gregory A Storch, Roberta L DeBiasi, Jin-Young Han, April Palmer, Leonard B Weiner, Joseph A Bocchini, Penelope H Dennehy, Adam Finn, Paul D Griffiths, Suzanne Luck, Kathleen Gutierrez, Natasha Halasa, James Homans, Andi L Shane, Michael Sharland, Kari Simonsen, John A Vanchiere, Charles R Woods, Diane L Sabo, Inmaculada Aban, Huichien Kuo, Scott H James, Mark N Prichard, Jill Griffin, Dusty Giles, Edward P Acosta, Richard J Whitley
BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS: We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks of therapy. The primary end point was the change in hearing in the better ear ("best-ear" hearing) from baseline to 6 months...
March 5, 2015: New England Journal of Medicine